Gosset Ownership
Private
Employees
~30
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Aqtual General Information
Aqtual has developed a proprietary technology that enables comprehensive measurement of gene regulation and epigenetic features using cell-free DNA from blood. Their initial product is a blood test to guide therapy management in rheumatoid arthritis by identifying biomarkers associated with treatment response. Pilot studies have shown promising results; larger prospective studies are underway or planned[1][2].
Contact Information
Website
Primary Industry
Molecular Diagnostics
Corporate Office
Hayward, California
United States
United States
Drug Pipeline
Cell-free DNA diagnostic test
Phase 1Key Partnerships
Genoa Ventures (investor/partner)[2], Manta Ray Ventures (investor/partner)[2], Yu Galaxy (investor/partner)[2]
Aqtual Funding
No funding data available
To view Aqtual's complete valuation and funding history, request access »